

Poster # 6786



A National Cancer Institute Comprehensive Cancer Center

Background


IL-7 is a non-redundant cytokine essential for T cell survival, proliferation and function. NT-I7 (efineptakin alfa; NeolmmuneTech, Inc, Rockville, MD), is a long-acting IL-7 composed of recombinant human IL-7 (rhIL-7) fused to a hybrid Fc antibody platform that has significantly improved the *in vivo* stability and half-life compared to rhIL-7.

DNA cancer neoantigen vaccines are a promising personalized cancer immunotherapy capable of generating strong anti-tumor immunity currently under investigation in clinical trials (e.g. NCT03199040, NCT03122106). A limitation of the platform is the short duration of neoantigen-specific T cell immunity.

NT-I7 (efineptakin alfa; a long-acting IL-7) Plasmid containing E0771 neoantigens

DNA Vaccine

IL-7 Domain HyFc[®] Domain



In this study, we test the addition of NT-I7 as an adjuvant to a validated polyepitope DNA neoantigen vaccine for the E0771 murine breast cancer model (DNA-E0771) containing three immunogenic neoantigens (Lrrc27, Plekho1, Pttg1)¹.

Hypothesis

- The addition of NT-I7 as an adjuvant to DNA neoantigen vaccine will prolong the duration of neoantigen-specific T cell immunity
- DNA neoantigen vaccine plus NT-I7 will generate improved antitumor responses compared to DNA vaccine alone


References


. Li, Lijin, et al. "Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation." Genome medicine 13 (2021): 1-13.

NT-I7 as an adjuvant to DNA neoantigen vaccination enhances and prolongs neoantigen-specific anti-tumor immunity

Michael Chen¹, Ina Chen¹, Suangson Supabphol¹, Alexandra A. Wolfarth², Sara Ferrando-Martinez², Byung Ha Lee², Lijin Li¹, Xiuli Zhang¹, S. Peter Goedgebuure^{1, 3}, William E. Gillanders^{1, 3}

¹Department of Surgery, Washington University School of Medicine; ²NeolmmuneTech, Inc.; ³The Alvin J. Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine






NT-I7 (5 mg/kg) was administered subcutaneously on day 4 or day 13 during the T cell expansion or contraction phase, respectively. The addition of NT-I7 to DNA vaccination during the expansion or contraction phase enhanced the magnitude of the neoantigen specific immunity on Day 20.

DNA-E0771 + NT-I7 generates stronger neoantigen-specific killing and memory CD8⁺ T cell responses NT-I7 Day 13 In vivo CTL Days 22, 41, 51 DNA Day 22 Days 0, 3, 6 DNA-E0771 - DNA-blank --- DNA-E0771 → NT-I7 → DNA-E0771 + NT-I7 40-ත <u>3</u>0-NT-17 DNA-E0771 + NT-I7 20-Days after start of vaccination

Mice were vaccinated with DNA vaccine with/without NT-I7. Then, 22, 41, and 51 days after start of vaccination, CFSE-labeled syngeneic splenocytes were pulsed with neoantigen peptides (low CFSE) and mixed with naïve splenocytes (high CFSE), then adoptively transferred into vaccinated mice. Flow cytometry was performed 16 hours later. Neoantigen-specific cytotoxicity is calculated by: % specific lysis = 1 – (%CFSEIo / %CFSEhi) × 100

DNA-E0771 + NT-I7 protects from tumor challenge



C57BL/6 mice were vaccinated with DNA vaccine on days 0, 3, and 6 and NT-I₇ (5mg/kg) administered on day 13. 5*10⁵ E0771 cells were inoculated subcutaneously on day 27 and tumor growth were tracked with electronic caliper.

Washington University in St.Louis SCHOOL OF MEDICINE

DNA-E0771 + NT-I7 increases neoantigen-specific TILs **Therapeutic Model** NT-I7 Expansio Dextramer analysis Tumor Day 11 Days 0, 3, 6 Dav -6 NT-I7 0.20 0.47 0 0 DNA-E0771 + NT-I7 **DNA-E077** 1.79 7.18 Ô. NT-I7 CD8

Lrrc27 dextramer+ TILs

model, DNA therapeutic vaccination in combination with increases neoantigenspecific CD8⁺ T cells in the tumor measured by Lrrc27 dextramer.

Conclusion

NT-I₇ as an adjuvant to a DNA neoantigen vaccine:

- 1) Increases the duration of neoantigen-specific anti-tumor immunity,
- 2) Protects from tumor challenge in a prophylactic murine model, and
- 3) Promotes neoantigen-specific TILs in a therapeutic murine model.

Clinical application of NT-I7 may help overcome immunologic shortcomings of current neoantigen vaccines.

Future Directions

- Determine the efficacy and mechanism of DNA-E0771 + NT-I7 in the therapeutic setting, and
- Continue to test DNA-E0771 + NT-I7 in the prophylactic setting to increase sample size and further define the mechanism of action

Funding

- Washington University T32 Surgical Oncology Research Training Grant (NIH T32CA009621)
- NIH R01 CA240983
- Alvin J. Siteman Cancer Center—Siteman Investment Program gram 4035

